Outcome of liver cancer patients with SARS‐CoV‐2 infection: an international, multicentre, cohort study

Muñoz‐Martínez, S. et al. (2022) Outcome of liver cancer patients with SARS‐CoV‐2 infection: an international, multicentre, cohort study. Liver International, 42(8), pp. 1891-1901. (doi: 10.1111/liv.15320) (PMID:35608939)

[img] Text
271704.pdf - Published Version
Available under License Creative Commons Attribution.



Background & Aims: Information about the impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients with liver cancer is lacking. This study characterizes the outcomes and mortality risk in this population. Methods: Multicenter retrospective, cross-sectional, international study of liver cancer patients with SARS-CoV-2 infection registered between February-December 2020. Clinical data at SARS-CoV-2 diagnosis and outcomes were registered. Results: Two-hundred-fifty patients from 38 centers were included, 218 with hepatocellular carcinoma (HCC), 32 with intrahepatic cholangiocarcinoma (iCCA). Median age was 66.5 and 64.5 years, and 84.9% and 21.9% had cirrhosis in the HCC and iCCA cohorts, respectively. Patients had advanced cancer stage at SARS-CoV-2 diagnosis in 39.0% of the HCC and 71.9% of the iCCA patients. After a median follow-up of 7.20 [IQR:1.84–11.24] months, 100 (40%) patients have died,48% of the deaths were SARS-CoV-2-related. Forty (18.4%) HCC patients died within 30-days. The death rate increase was significantly different according to the BCLC stage [6.10%(95%CI 2.24–12.74), 11.76%(95%CI 4.73–22.30), 20.69%(95%CI 11.35–31.96), and 34.52%(95%CI 17.03–52.78) for BCLC 0/A, B, C and D respectively; p=0.0017]. The Hazard Ratio was 1.45 (95%CI 0.49–4.31; p=0.5032) in BCLC-B vs 0/A, and 3.13 (95%CI 1.29–7.62; p=0.0118) in BCLC-C vs 0/A in the Competing risk Cox regression model. Nineteen out of 32 iCCA (59.4%) died, 12 deaths related to SARS-CoV-2 infection. Conclusions: This is the largest cohort of liver cancer patients infected with SARS-CoV-2. It characterizes the 30-day mortality risk of SARS-CoV-2 infected patients with HCC during this period.

Item Type:Articles
Glasgow Author(s) Enlighten ID:Braconi, Dr Chiara
Authors: Muñoz‐Martínez, S., Sapena, V., Forner, A., Bruix, J., Sanduzzi‐Zamparelli, M., Ríos, J., Bouattour, M., El Kassas, M., Leal, C. R. G., Mocan, T., Nault, J.‐C., Alves, R. C. P., Reeves, H. L., Fonseca, L., García‐Juárez, I., Pinato, D. J., Varela, M., Alqahtani, S. A., Alvares‐da‐Silva, M. R., Bandi, J. C., Rimassa, L., Lozano, M., González Santiago, J. M., Tacke, F., Sala, M., Anders, M., Lachenmayer, A., Piñero, F., França, A., Guarino, M., Elvevi, A., Cabibbo, G., Peck‐Radosavljevic, M., Rojas, Á., Vergara, M., Braconi, C., Pascual, S., Perelló, C., Mello, V., Rodríguez‐Lope, C., Acevedo, J., Villani, R., Hollande, C., Vilgrain, V., Tawheed, A., Ferguson Theodoro, C., Sparchez, Z., Blaise, L., Viera‐Alves, D. E., Watson, R., Carrilho, F. J., Moctezuma‐Velázquez, C., D'Alessio, A., Iavarone, M., and Reig, M.
College/School:College of Medical Veterinary and Life Sciences > School of Cancer Sciences
Journal Name:Liver International
ISSN (Online):1478-3231
Published Online:24 May 2022
Copyright Holders:Copyright © 2022 The Authors
First Published:First published in Liver International 2022
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record